Journal
CANCERS
Volume 14, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/cancers14122819
Keywords
MALINC1; lncRNA; breast cancer; DCIS
Categories
Funding
- Office of the Assistant Secretary of Defense for Health Affairs through the Breast Cancer Research Program [W81XWH-16-1-0027, BC150021]
- Argentine National Agency of Scientific and Technological Promotion [PICT-2018-01403]
Ask authors/readers for more resources
This study characterizes the phenotypic and molecular effects of MALINC1, a long non-coding RNA (lncRNA) that is upregulated in premalignant ductal carcinoma in-situ lesions. MALINC1 is found to behave as an oncogenic and immune-related lncRNA involved in early-stage breast cancer progression. High expression of MALINC1 is associated with a pro-tumorigenic immune environment and a favorable predicted response to immunotherapy.
Simple Summary Here we characterize the phenotypic and molecular effects of MALINC1, a long non-coding RNA (lncRNA) that we found significantly upregulated in premalignant ductal carcinoma in-situ lesions. We provide evidence that MALINC1 behaves as an oncogenic and immune-related lncRNA involved with early-stage breast cancer progression, showing prognostic and predictive value to immunotherapy in invasive breast carcinomas. Long non-coding RNAs are increasingly being recognized as cancer biomarkers in various malignancies, acting as either tumor suppressors or oncogenes. The long non-coding MALINC1 intergenic RNA was identified as significantly upregulated in breast ductal carcinoma in situ. The aim of this study was to characterize MALINC1 expression, localization, and phenotypic and molecular effects in non-invasive and invasive breast cancer cells. We determined that MALINC1 is an estrogen-estrogen receptor-modulated lncRNA enriched in the cytoplasmic fraction of luminal A/B breast cancer cells that is associated with worse overall survival in patients with primary invasive breast carcinomas. Transcriptomic studies in normal and DCIS cells identified the main signaling pathways modulated by MALINC1, which mainly involve bioprocesses related to innate and adaptive immune responses, extracellular matrix remodeling, cell adhesion, and activation of AP-1 signaling pathway. We determined that MALINC1 induces premalignant phenotypic changes by increasing cell migration in normal breast cells. Moreover, high MALINC1 expression in invasive carcinomas was associated with a pro-tumorigenic immune environment and a favorable predicted response to immunotherapy both in luminal and basal-like subtypes compared with low-MALINC1-expression tumors. We conclude that MALINC1 behaves as an oncogenic and immune-related lncRNA involved with early-stage breast cancer progression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available